Corbevax maximises protection in Covishield vaccinated people: Study
Amidst the concerns of a new Covid wave in India following massive surge in cases in some countries, researchers at the AIG Hospitals here have published results of a significant scientific study proving the immunity benefits of indigenous heterologous vaccine booster, Corbevax in combating Omicron variants.
Breaking down the key aspects of the study, Dr D Nageshwar Reddy, Chairman, AIG Hospitals and one of the researchers on board, in a press release said the study was done on 250 healthcare workers who had received two doses of Covishield as the primary vaccine regimen not more than 6 months ago.
"The first aspect was to test the safety of this combination. We are extremely happy to report that none of the 250 participants had any adverse events following the administration of Corbevax booster dose. This further cemented our belief that mixed vaccines are absolutely safe," Dr Reddy said.
The second aspect of the study was to measure the antibody response as well as the T-cell ...